Diabetes is one of the largest global health emergencies of the 21st century. Each year more and more people live with this condition, which can result in life-changing complications. In addition to the 415 million adults who are estimated to have diabetes globally in 2015, there are 318 million adults with impaired glucose tolerance, which puts them at high risk of developing the chronic disease in the future. The incidence & prevalence of diabetes is growing with rising obesity rates, changing lifestyle and dietary habits, and growing ageing population. Therefore, given the huge numbers of diabetics worldwide and the huge financial implications associated with diabetes and related further health complications, there is a substantial market potential in the global diabetes care devices & drugs market in the next 5-10 years. The global diabetes care devices & drugs market are expected to grow at a CAGR of 5.2% from 2017 to 2022 to reach $85,591.2 million by 2022.
Following a comprehensive research on the global diabetes care devices & drugs market and an in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, and opportunities, listed in the market insights segment. Increasing incidence & prevalence of diabetes, technological advancements, rise in obesity, and increasing sedentary lifestyle and improper diet are the key market drivers covered in the report which will support the industry growth in the forecast period. However, high cost associated with diagnosis and treatment, reimbursement issues, and lack of awareness are the major pain points, restraining the adoption of the diabetes care devices & drugs market in various countries across the globe.
The report further gives an extensive outlook on the multifarious segments and sub-segments in both diabetes care devices and drugs market. The diabetes care devices market further talks about the trends impacting the growth of diabetes monitoring devices and insulin delivery devices including their sub-segments. The diabetes care drugs market in detail speaks about insulin, oral-hypoglycemic drugs, and non-insulin injectable drugs.
An exhaustive analysis of the geographical scenario of the industry for the five major geographies: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa is included in the geographical analysis section. These regions are further analyzed at a country level with the detailed qualitative and quantitative analysis. The geographical analysis provides detailed insights on the key trends of the industry in the listed regions & countries, identifying the disease incidence & prevalence, demographic & economic impact, government & private investments, and regulatory scenario. The report identifies North America to be the largest market, followed by Europe, Asia-Pacific, Latin America and Middle East & Africa. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective countries.
Click here to: Get Free Sample Pages of this Report
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 3 years (2015-2017). The study has also incorporated the market share analysis of leading players in each of the diabetes care devices and drugs market, and detailed profiles of 15 top market players across the value chain of the industry, including detailed financial performance, product offerings, and strategic growth initiatives of each player.
The key players operating in the global diabetes care devices & drugs market are Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), Eli Lilly and Company (U.S.), Hoffmann-La Roche Ltd.(Switzerland), Johnson & Johnson (U.S.), Medtronic PLC (Ireland), Becton, Dickinson and Company (U.S.), Terumo Corporation (Japan), Sanofi S.A. (France), Merck & Co., Inc.(U.S.), Novartis AG (Switzerland), AstraZeneca PLC (U.K.), and Boehringer Ingelheim GmbH (Germany).
Scope of the Report:
Market by Product
Diabetes care devices
- Diabetes monitoring devices
- Test strips
- Self-monitoring devices
- Continuous blood glucose monitoring devices
- Lancets
- Hemoglobin A1c testing kits
- Insulin delivery devices
- Insulin Pens
- Insulin Syringes
- Insulin Pumps
- Insulin Jet Injectors
Diabetes care drugs
- Insulin
- Rapid-acting insulin drugs
- Short-acting insulin drugs
- Intermediate-acting insulin drugs
- Long-acting insulin drugs
- Oral-hypoglycaemic drugs
- Biguanides (Metformin)
- Sulfonylureas
- Meglitinides/ Phenylalanine analogues
- Thiazolidinedione analogues
- α-glucosidase inhibitors
- DPP-IV Inhibitors
- Non-insulin injectable drugs
Market by Geography
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- Rest of World
- Latin America
- The Middle East and Africa
Key questions answered in the report:
Increasing prevalence of diabetes drive the adoption of Diabetes care devices & drugs market.
-
- How does the penetration of oral-hypoglycaemic agents in healthcare industry differ from the penetration insulins?
- Which are the high growth market segments in terms of types of diabetes care devices & diabetes drugs market and regions/countries?
Insulin delivery devices account for a relatively small proportion of the diabetes care devices of diabetes care devices & drugs globally
-
- What factors contribute to the infrequent usage of insulin delivery devices in healthcare sector?
- Conversely, which geographic segment is expected to experience the fastest growth for on insulin delivery devices.
The North American diabetes care devices & drugs market favors both larger and local manufacturers that compete in multiple segments
-
- What are the top competitors in this market and what strategies do they employ to gain shares?
- What is driving growth and which market segments have the most potential for revenue expansion over the forecast period?
- What strategies should new companies looking to enter this market use to compete effectively?
- What are the major drivers, restrains, opportunities, and trends in the global diabetes care devices & drugs market?
- Who are the major players in various countries and what share of the market do they hold?
- What are the geographical trends and high growth regions/ countries?
Recent partnerships, agreements, and expansions have taken place in the diabetes care devices & drugs market space.
-
- What companies have recently merged/acquired and how will these unions affect the competitive landscape of the diabetes care devices & drugs space?
- What companies have created partnerships and how will these partnerships promote a competitive advantage?
- Who are the major players in the Global Diabetes Care Devices & Drugs market and what share of the market do they hold?
- What are the local emerging players in the Global Diabetes Care Devices & Drugs market and how do they compete with the global players?
